Supriya Lifescience Limited (SUPRIYA) AI Stock Analysis

• Market Cap: ₹53.13B
• Dividend Yield: 0.12%
• Average Volume (3M): 9.95K
• Price to Earnings (P/E): 29.8
• Beta (1Y): 1.13
• Revenue Growth: 13.68%
• EPS Growth: 31.69%
• Country: IN
• Employees: 448
• Sector: Healthcare
• Sector Strength: 49
• Industry: Biotechnology
• EPS (TTM): 4.30
• Shares Outstanding: 80,482,800
• 10 Day Avg. Volume: 5,480
• 30 Day Avg. Volume: 9,946
• PEG Ratio: N/A
• Price to Book (P/B): N/A
• Price to Sales (P/S): N/A
• P/FCF Ratio: N/A
• Enterprise Value/Market Cap: N/A
• Enterprise Value/Revenue: N/A
• Enterprise Value/Gross Profit: N/A
• Enterprise Value/Ebitda: N/A
• 1Y Price Target: ₹718.00
• Price Target Upside: 9.50% Upside
• Rating Consensus: Hold
• Number of Analyst Covering: 0

• Rating: 67 Neutral
• Price Target: ₹718.00 ▲(9.50% Upside)

Supriya Lifescience's strong financial performance is the primary driver of its stock score, reflecting robust revenue growth and improved profitability. However, technical analysis indicates bearish momentum, and the stock's valuation appears high with a low dividend yield, which tempers the overall score.

Supriya Lifescience Limited Business Overview & Revenue Model

Company Description

Supriya Lifescience Limited (SUPRIYA) is a prominent player in the pharmaceuticals industry, specializing in the manufacturing and distribution of active pharmaceutical ingredients (APIs). The company has established itself as a trusted supplier to pharmaceutical companies globally, offering a diverse portfolio that caters to a wide range of therapeutic categories. With a commitment to quality and innovation, Supriya Lifescience focuses on providing high-quality products that meet international standards.

How the Company Makes Money

Supriya Lifescience Limited generates revenue primarily through the production and sale of active pharmaceutical ingredients (APIs). These APIs are sold to pharmaceutical companies who use them in the formulation of various medications. The company's revenue streams are bolstered by its diversified product portfolio, which spans multiple therapeutic areas, ensuring a stable demand across different segments of the pharmaceutical market. Additionally, Supriya Lifescience may engage in strategic partnerships and long-term supply agreements with key players in the industry to secure steady revenue inflows. The company’s focus on maintaining stringent quality controls and adhering to regulatory standards further enhances its reputation, allowing it to command a premium for its products and sustain profitability.

Supriya Lifescience Limited Financial Statement Overview

Summary

Supriya Lifescience exhibits a robust financial position with strong growth in revenue and profitability, supported by sound balance sheet metrics and improving cash flow management. The company's strategic focus on reducing leverage and enhancing equity has positioned it well for future growth, though attention to cash flow stability will be beneficial.

Income Statement

Supriya Lifescience has demonstrated strong income statement performance with robust revenue growth, increasing from ₹3,116 million in 2020 to ₹6,965 million in 2025. Net Profit Margin improved from 23.5% in 2020 to 27.0% in 2025, indicating enhanced profitability. However, the Gross Profit Margin slightly decreased from 47.8% in 2020 to 55.2% in 2025, suggesting cost efficiency improvements. Consistent growth in EBIT and EBITDA margins further highlight the company's operational effectiveness.

Balance Sheet

The balance sheet is strong with a high Equity Ratio, improving from 44.3% in 2020 to 89.6% in 2025, indicating a solid equity base. The Debt-to-Equity Ratio has significantly reduced, showcasing decreased leverage and financial risk. Return on Equity remains healthy, bolstered by consistent net income growth. The company's prudent financial management is evident in its reduced liabilities and increased equity over the years.

Cash Flow

Supriya Lifescience shows a positive trajectory in cash flow management, with Free Cash Flow turning positive in 2025 after a negative trend. Operating Cash Flow compared to Net Income is strong, indicating efficient cash generation from operations. However, fluctuations in Free Cash Flow over the years highlight potential volatility in capital expenditures and investment strategies.

Breakdown	TTM	Dec 2025	Dec 2024	Dec 2022	Dec 2022	Dec 2021
Income Statement
Total Revenue	6.71B	6.96B	5.57B	5.19B	4.61B	3.85B
Gross Profit	3.86B	3.84B	2.80B	2.89B	2.80B	2.34B
EBITDA	2.58B	2.71B	1.84B	2.22B	1.38B	1.78B
Net Income	1.75B	1.88B	1.19B	1.52B	898.57M	1.24B
Balance Sheet
Total Assets	0.00	11.12B	9.21B	7.35B	8.20B	4.46B
Cash, Cash Equivalents and Short-Term Investments	843.14M	791.54M	727.37M	2.25B	1.64B	894.43M
Total Debt	0.00	53.80M	54.88M	274.15M	224.68M	721.94M
Total Liabilities	-9.06B	1.16B	1.06B	1.19B	1.21B	1.77B
Stockholders Equity	9.06B	9.97B	8.15B	6.16B	6.99B	2.69B
Cash Flow
Free Cash Flow	0.00	101.89M	-323.48M	-111.03M	-422.13M	316.89M
Operating Cash Flow	0.00	1.73B	1.13B	488.01M	661.87M	799.30M
Investing Cash Flow	0.00	-1.62B	-1.74B	-598.22M	-1.33B	-474.10M
Financing Cash Flow	0.00	-65.47M	-223.59M	1.50B	-33.68M	-149.31M

Supriya Lifescience Limited Technical Analysis

• Technical Analysis Sentiment: Negative
• Last Price: 655.70
• 50DMA: Negative
• 100DMA: Negative
• 200DMA: Negative
• MACD: Negative
• RSI: Neutral
• STOCH: Neutral

Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:SUPRIYA, the sentiment is Negative. The current price of 655.7 is below the 20-day moving average (MA) of 661.99, below the 50-day MA of 681.92, and below the 200-day MA of 695.64, indicating a bearish trend. The MACD of -5.50 indicates Negative momentum. The RSI at 44.14 is Neutral, neither overbought nor oversold. The STOCH value of 29.98 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:SUPRIYA.

Supriya Lifescience Limited Peers Comparison

Name	Overall Rating	Market Cap	P/E Ratio	ROE	Dividend Yield	Revenue Growth	EPS Growth
SUPRIYA	67 Neutral	₹53.13B	29.83		0.12%	13.68%	31.69%
AARTIDRUGS	66 Neutral	₹43.29B	23.69		0.20%	-0.03%	21.33%
GUFICBIO	55 Neutral	₹36.77B	59.44		0.03%	2.37%	-30.78%
SEQUENT	52 Neutral	₹43.03B	148.54		―	12.33%	439.46%
Sector *	51 Neutral	$7.91B	-0.36	-41.71%	2.23%	23.45%	-1.86%
SPARC	41 Neutral	₹46.65B	―		―	-5.57%	23.03%
SUVEN	―	₹48.22B	―		―	―	―